SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bioterrorism
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates2/2/2007 4:53:27 AM
   of 891
 
Bavarian Nordic, GlaxoSmithKline stop smallpox vaccine venture

COPENHAGEN (AFX) - Bavarian Nordic AS said it has agreed with GlaxoSmithKline (LSE: GSK.L - news) not to pursue their collaboration for producing and marketing Imvamune, a third-generation smallpox vaccine currently under development.
The two companies signed a memorandum of understanding in 2004 to ensure sufficient production capacity from several facilities, and distribution of the vaccine to various international markets, at a time where Bavarian Nordic (Copenhagen: BAVA.CO - news) 's own production facility was not established.
Bavarian Nordic said it now has the capacity to produce the expected orders.
Production, marketing and distribution of Imvamune will be handled by Bavarian Nordic's own production facility and sales organisation in tandem with local and regional agents and distributors experienced in handling government contracts.
The termination of the agreement will have no negative financial consequences for Bavarian Nordic or GSK.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News